Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Elevated Plasma Levels of Urokinase Plasminogen Activator Receptor in Non-small Cell Lung Cancer Patients

By Pappot H.   Hoyer-Hansen G.   Ronne E.   Hansen H.H.   Brunner N.   Dano K.   Grondahl-Hansen J.  

European Journal of Cancer, Vol. 33, Iss. 6, 1997-05 ,pp. : 867-872

Elsevier

Access to resources Recommend Favorite

Fatty Acid Composition of Lysophosphatidic Acid and Lysophosphatidylinositol in Plasma from Patients with Ovarian Cancer and Other Gynecological Diseases

By Shen Z.   Wu M.   Elson P.   Kennedy A.W.   Belinson J.   Casey G.   Xu Y.  

Gynecologic Oncology, Vol. 83, Iss. 1, 2001-10 ,pp. : 25-30

Elsevier

Access to resources Recommend Favorite

Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

By              

Oncology Letters, Vol. 2, Iss. 4, 2011-01 ,pp. : 693-699

Spandidos Publications

Access to resources Recommend Favorite

Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis

By                            

Oncology Letters, Vol. 10, Iss. 4, 2015-01 ,pp. : 2403-2409

Spandidos Publications

Access to resources Recommend Favorite